September 2018

Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The self-tests, which use the innovative AtomoRapid platform, will allow individuals to confidently screen themselves...

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...

From its impressive and newly expanded manufacturing plant close to the beautiful village of Guipry in northwest France, NG Biotech is rapidly scaling-up production to meet growing demand for its innovative products. The village setting is in stark contrast to the cutting-edge nature of NG...